Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis
Kwonmok Ko, Emma I Kopra, Anthony J. Cleare, et al.
Journal of Affective Disorders (2022) Vol. 322, pp. 194-204
Closed Access | Times Cited: 84

Showing 1-25 of 84 citing articles:

History repeating: guidelines to address common problems in psychedelic science
Michiel van Elk, Eiko I. Fried
Therapeutic Advances in Psychopharmacology (2023) Vol. 13
Open Access | Times Cited: 51
Management of Depression in Adults
Gregory E. Simon, Nathalie Moise, David C. Mohr
JAMA (2024) Vol. 332, Iss. 2, pp. 141-141
Closed Access | Times Cited: 26
Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study
Joost J. Breeksema, Alistair Niemeijer, Erwin Krediet, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 18
Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis
Athina-Marina Metaxa, Mike Clarke
BMJ (2024), pp. e078084-e078084
Open Access | Times Cited: 17
A Systematic Review of Participant Diversity in Psychedelic-Assisted Psychotherapy Trials
Stephanie L. Haft, Amanda E. Downey, Marissa Raymond‐Flesch, et al.
Psychiatry Research (2025) Vol. 345, pp. 116359-116359
Open Access | Times Cited: 3
Discovering the Potential Mechanisms of Medicinal Mushrooms Antidepressant Activity: A Review
Jan Lazur, Kamil Hnatyk, Katarzyna Kała, et al.
Antioxidants (2023) Vol. 12, Iss. 3, pp. 623-623
Open Access | Times Cited: 34
History repeating: A roadmap to address common problems in psychedelic science
Michiel van Elk, Eiko I. Fried
(2023)
Open Access | Times Cited: 23
Giving Consent to the Ineffable
Daniel Villiger
Neuroethics (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 10
Antidepressant- and anxiolytic-like activities and acute toxicity evaluation of the Psilocybe cubensis mushroom in experimental models in mice
Alberto Hernández-León, Raúl Iván Escamilla-Orozco, Aylín R. Tabal-Robles, et al.
Journal of Ethnopharmacology (2023) Vol. 320, pp. 117415-117415
Closed Access | Times Cited: 16
The effect of psychedelics on the level of brain-derived neurotrophic factor: A systematic review and meta-analysis
Arman Shafiee, Razman Arabzadeh Bahri, M. Rafiei, et al.
Journal of Psychopharmacology (2024) Vol. 38, Iss. 5, pp. 425-431
Closed Access | Times Cited: 7
Mind the Psychedelic Hype: Characterizing the Risks and Benefits of Psychedelics for Depression
Daniel Meling, Rebecca Ehrenkranz, Sandeep M. Nayak, et al.
Psychoactives (2024) Vol. 3, Iss. 2, pp. 215-234
Open Access | Times Cited: 6
In the new era of psychedelic assisted therapy: A systematic review of study methodology in randomized controlled trials
Paul Soliman, Dallece E. Curley, Christy Capone, et al.
Psychopharmacology (2024) Vol. 241, Iss. 6, pp. 1101-1110
Closed Access | Times Cited: 6
Psychedelic treatments for mental health conditions pose challenges for informed consent
Carolina Seybert, Gonçalo Cotovio, Luís Madeira, et al.
Nature Medicine (2023) Vol. 29, Iss. 9, pp. 2167-2170
Closed Access | Times Cited: 15
Predicting the Intensity of Psychedelic-Induced Mystical and Challenging Experience in a Healthy Population: An Exploratory Post-Hoc Analysis
Kwonmok Ko, Ben Carter, Anthony J. Cleare, et al.
Neuropsychiatric Disease and Treatment (2023) Vol. Volume 19, pp. 2105-2113
Open Access | Times Cited: 13
Efficacy and acceptability of psilocybin for primary or secondary depression: A systematic review and meta-analysis of randomized controlled trials
Shuping Fang, Xin Yang, Wei Zhang
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 5
Personal psychedelic experience of psychedelic therapists during training: should it be required, optional, or prohibited?
Daniel Villiger
International Review of Psychiatry (2024), pp. 1-10
Open Access | Times Cited: 5
Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis
Tien‐Wei Hsu, Chia‐Kuang Tsai, Yu‐Chen Kao, et al.
BMJ (2024), pp. e078607-e078607
Open Access | Times Cited: 5
A rapid narrative review of the clinical evolution of psychedelic treatment in clinical trials
Ronit Kishon, Nadav Liam Modlin, Yael M. Cycowicz, et al.
npj Mental Health Research (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 4
Psilocybin for major depressive disorder: a systematic review of randomized controlled studies
Lijuan Li, Mo Yu, Zhan-Ming Shi, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 4
Self‐reported experiences and perspectives on using psychedelics to manage opioid use among participants of two Reddit communities
Noa Krawczyk, Megan Miller, Emma Yuanqi Gu, et al.
Addiction (2025)
Closed Access
Investigating novel pharmacological strategies for treatment-resistant depression: focus on new mechanisms and approaches
Aline Silva de Miranda, Eliana Cristina de Brito Toscano, Venugopal Reddy Venna, et al.
Expert Opinion on Drug Discovery (2025), pp. 1-15
Closed Access
Mental disorder and its treatment as a transformative experience
Daniel Villiger
Phenomenology and the Cognitive Sciences (2025)
Open Access
Psychedelic-assisted Therapy as a Promising Treatment for Irritable Bowel Syndrome
Erin E. Mauney, Franklin King, Helen Burton Murray, et al.
Journal of Clinical Gastroenterology (2025)
Closed Access
Irremediable Psychiatric Suffering, a Potential Indication for Psilocybin Treatment
Metten Somers, Floortje E. Scheepers
American Journal of Psychiatry (2025) Vol. 182, Iss. 3, pp. 243-246
Closed Access
The Faithful Response to the Comforting Delusion Objection
Adrian Kind
Neuroethics (2025) Vol. 18, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top